Lynparza (olaparib) — United Healthcare

Initial criteria

• Diagnosis of uterine sarcoma
• Not used as first-line therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Lynparza therapy

Approval duration

12 months